Is VRTX a good stock to buy? We came across a bullish thesis on Vertex Pharmaceuticals Incorporated in r/AIPortfolios by manojs. In this article we will summarize the bulls’ thesis on VRTX. Vertex Pharmaceuticals Incorporated stock was trading at $454.08 on March 20. VRTX’s trailing and forward P/E were 29.63 and 23.81 respectively, according to Yahoo Finance.
robina-weermeijer–szKjHyPq28-unsplash
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe and internationally. VRTX has attracted the attention of bullish investors following its positive portfolio performance and solid financial positioning. The company’s outlook is supported by povetacicept’s interim Phase 3 success in IgA nephropathy, which demonstrated a 49.8% reduction in proteinuria, de-risking the asset and fueling a 6.58% stock rally on March 9, accompanied by analyst upgrades.
Read more: 15 AI Stocks That Are Quietly Making Investors Rich
Read more: Undervalued AI Stocks Poised for Massive Gains: 10000% Upgrade Potential
Vertex plans to file a progressive BLA by the end of March 2026, presenting a near-term regulatory catalyst with potential for accelerated approval. Beyond povetacicept, the company’s non-CF portfolio shows solid momentum: Journavx prescriptions are expected to triple in 2026 and Gernavix Phase 4 data are imminent, highlighting significant future growth potential. Financially, Vertex remains strong, with a 10% year-over-year increase in fourth-quarter revenue and 2026 guidance indicating top-line growth of 8% to 9%, while $12.3 billion in cash provides ample resources to fund ongoing R&D initiatives.
Broader tailwinds from the biotech sector, including lower Treasury yields to 4.13% and fed funds yields to 3.64%, further support growth-oriented stocks like VRTX. Technically, the stock shows a neutral to positive setup, trading near key moving averages with an RSI of 51, while analysts’ price targets average $550, implying roughly 15% upside from the recent close of $479.98. Overall, Vertex combines strong near-term regulatory catalysts, expanding pipeline opportunities, strong financial health and favorable sector dynamics, making it a compelling growth-focused investment with growth potential and manageable risk.
Previously, we covered a bullish thesis on CRISPR Therapeutics AG (CRSP) by MADD-Scientis in March 2025, which highlighted Casgevy’s commercial potential, strong gene editing portfolio, low dilution risk, and favorable macro biotech trends. The CRSP share price has appreciated approximately 12.86% since our coverage. Manojs shares a similar view, but emphasizes the success of Vertex Pharmaceuticals Incorporated’s Phase 3 povetacicept and near-term regulatory catalysts.